Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration
Zengin Z, Henderson N, Park J, Ali A, Nguyen C, Hwang C, Barata P, Bilen M, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin V, Patel V, Schweizer M, Armstrong A, McKay R, Alva A, Dorff T. Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration. Prostate Cancer And Prostatic Diseases 2024, 1-7. PMID: 38383885, DOI: 10.1038/s41391-024-00805-3.Peer-Reviewed Original ResearchAndrogen receptor-targeted agentsCastration-resistant prostate cancerAR alterationsAR amplificationAR mutationsProstate cancerGene alterationsClinical outcomesAssociated with longer time to progressionCastration-resistant prostate cancer patientsGenomic testingLonger time to progressionTime to progressionAdvanced prostate cancerReceptor-targeted agentsPSA responseMetastatic diseaseOverall survivalMulti-institutional collaborative effortTestosterone suppressionMedian ageTargeted agentsProspective studyTreatment outcomesTherapeutic strategies